The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
1039522510 10395225 10 F 201212 20160707 20140820 20160721 EXP FR-009507513-1406FRA001917 MERCK 52.00 YR F Y 0.00000 20160721 CN CA FR

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
1039522510 10395225 1 PS VICTRELIS BOCEPREVIR 1 Oral 4 CAPSULES THREE TIMES A DAY, TOTAL DAILY DOSE: 12 CAPS, TO START AFTER 4 WEEKS OF BI THERAPY Y 202258 4 DF CAPSULE TID
1039522510 10395225 2 SS COPEGUS RIBAVIRIN 1 Oral 5 TABS, QD (2 TABLETS IN THE MORNING AND 3 TABLETS IN THE EVENING) Y 0 5 DF TABLET QD
1039522510 10395225 3 SS PEGASYS PEGINTERFERON ALFA-2A 1 Subcutaneous 1 INJECTION, QW Y 0 1 DF /wk
1039522510 10395225 4 C ASCORBIC ACID. ASCORBIC ACID 1 Oral 1 TABLET, IN THE MORNING U 0 1 DF TABLET QD
1039522510 10395225 5 C TOCO UNSPECIFIED INGREDIENT 1 Oral 1 TAB, QAM U 0 1 DF TABLET QD
1039522510 10395225 6 C DAFALGAN ACETAMINOPHEN 1 Oral UNK U 0 CAPSULE

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
1039522510 10395225 1 Hepatitis C
1039522510 10395225 2 Hepatitis C
1039522510 10395225 3 Hepatitis C

Outcome of event

Event ID CASEID OUTC COD
1039522510 10395225 HO
1039522510 10395225 OT
1039522510 10395225 DS

Reactions reported

Event ID CASEID DRUG REC ACT PT
1039522510 10395225 Asthenia
1039522510 10395225 Depression
1039522510 10395225 Disturbance in attention
1039522510 10395225 Dry skin
1039522510 10395225 Dysgeusia
1039522510 10395225 Epistaxis
1039522510 10395225 Fatigue
1039522510 10395225 Haemorrhage
1039522510 10395225 Hallucination
1039522510 10395225 Headache
1039522510 10395225 Heart rate increased
1039522510 10395225 Hepatic cirrhosis
1039522510 10395225 Hepatic steatosis
1039522510 10395225 Hyperthermia
1039522510 10395225 Hypothyroidism
1039522510 10395225 Influenza
1039522510 10395225 Insomnia
1039522510 10395225 Irritability
1039522510 10395225 Malaise
1039522510 10395225 Memory impairment
1039522510 10395225 Metrorrhagia
1039522510 10395225 Muscle spasms
1039522510 10395225 Neck pain
1039522510 10395225 Neutropenia
1039522510 10395225 Ophthalmic herpes zoster
1039522510 10395225 Pain
1039522510 10395225 Palpitations
1039522510 10395225 Panic attack
1039522510 10395225 Pelvic pain
1039522510 10395225 Photophobia
1039522510 10395225 Rash
1039522510 10395225 Therapy non-responder
1039522510 10395225 Thrombocytopenia
1039522510 10395225 Urinary tract infection
1039522510 10395225 Visual impairment

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
1039522510 10395225 1 20121221 20131025 0
1039522510 10395225 2 20121123 20131025 0
1039522510 10395225 3 20121123 20131025 0